Article
Effectiveness of EGFR tyrosine kinase inhibitors in advanced non-small cell lung cancer patients with uncommon EGFR mutations: A multicenter observational study.
Thoracic cancer - 1 Jan 2021
Kanazu Masaki, Mori Masahide, Kimura Madoka, Nishino Kazumi, Shiroyama Takayuki, Nagatomo Izumi, Ihara Shoichi, Komuta Kiyoshi, Suzuki Hidekazu, Hirashima Tomonori, Kumagai Toru, Imamura Fumio
Abstract excerpt
BACKGROUND: Epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy is the standard treatment for advanced non-small cell lung cancer (NSCLC) harboring common EGFR mutations, such as exon 19 deletion or L858 point mutation. However, the effectiveness of EGFR-TKIs for patients with uncommon EGFR mutations remains unclear. METHODS: We retrospectively surveyed a consecutive database of NSCLC...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.